Cargando…
Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors?
SGLT-2i are the new standard of care for diabetic kidney disease (DKD), but previous studies have not included patients on kidney replacement therapy (KRT). Due to their high risk of cardiovascular, renal complications, and mortality, these patients would benefit the most from this therapy. Residual...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377393/ https://www.ncbi.nlm.nih.gov/pubmed/37509547 http://dx.doi.org/10.3390/biomedicines11071908 |
_version_ | 1785079506647646208 |
---|---|
author | De La Flor, José C. Villa, Daniel Cruzado, Leónidas Apaza, Jacqueline Valga, Francisco Zamora, Rocío Marschall, Alexander Cieza, Michael Deira, Javier Rodeles, Miguel |
author_facet | De La Flor, José C. Villa, Daniel Cruzado, Leónidas Apaza, Jacqueline Valga, Francisco Zamora, Rocío Marschall, Alexander Cieza, Michael Deira, Javier Rodeles, Miguel |
author_sort | De La Flor, José C. |
collection | PubMed |
description | SGLT-2i are the new standard of care for diabetic kidney disease (DKD), but previous studies have not included patients on kidney replacement therapy (KRT). Due to their high risk of cardiovascular, renal complications, and mortality, these patients would benefit the most from this therapy. Residual kidney function (RKF) conveys a survival benefit and cardiovascular health among hemodialysis (HD) patients, especially those on incremental hemodialysis (iHD). We retrospectively describe the safety and efficacy of SGLT2i regarding RKF preservation in seven diabetic patients with different clinical backgrounds who underwent iHD (one or two sessions per week) during a 12-month follow-up. All patients preserved RKF, measured as residual kidney urea clearance (KrU) in 24 h after the introduction of SGLT2i. KrU levels improved significantly from 4.91 ± 1.14 mL/min to 7.28 ± 1.68 mL/min at 12 months (p = 0.028). Pre-hemodialysis blood pressure improved 9.95% in mean systolic blood pressure (SBP) (p = 0.015) and 10.95% in mean diastolic blood pressure (DBP) (p = 0.041); as a result, antihypertensive medication was modified. Improvements in blood uric acid, hemoglobin A1c, urine albumin/creatinine ratio (UACR), and 24 h proteinuria were also significant. Regarding side effects, two patients developed uncomplicated urinary tract infections that were resolved. No other complications were reported. The use of SGLT2i in our sample of DKD patients starting iHD on a 1–2 weekly regimen appears to be safe and effective in preserving RKF. |
format | Online Article Text |
id | pubmed-10377393 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103773932023-07-29 Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors? De La Flor, José C. Villa, Daniel Cruzado, Leónidas Apaza, Jacqueline Valga, Francisco Zamora, Rocío Marschall, Alexander Cieza, Michael Deira, Javier Rodeles, Miguel Biomedicines Case Report SGLT-2i are the new standard of care for diabetic kidney disease (DKD), but previous studies have not included patients on kidney replacement therapy (KRT). Due to their high risk of cardiovascular, renal complications, and mortality, these patients would benefit the most from this therapy. Residual kidney function (RKF) conveys a survival benefit and cardiovascular health among hemodialysis (HD) patients, especially those on incremental hemodialysis (iHD). We retrospectively describe the safety and efficacy of SGLT2i regarding RKF preservation in seven diabetic patients with different clinical backgrounds who underwent iHD (one or two sessions per week) during a 12-month follow-up. All patients preserved RKF, measured as residual kidney urea clearance (KrU) in 24 h after the introduction of SGLT2i. KrU levels improved significantly from 4.91 ± 1.14 mL/min to 7.28 ± 1.68 mL/min at 12 months (p = 0.028). Pre-hemodialysis blood pressure improved 9.95% in mean systolic blood pressure (SBP) (p = 0.015) and 10.95% in mean diastolic blood pressure (DBP) (p = 0.041); as a result, antihypertensive medication was modified. Improvements in blood uric acid, hemoglobin A1c, urine albumin/creatinine ratio (UACR), and 24 h proteinuria were also significant. Regarding side effects, two patients developed uncomplicated urinary tract infections that were resolved. No other complications were reported. The use of SGLT2i in our sample of DKD patients starting iHD on a 1–2 weekly regimen appears to be safe and effective in preserving RKF. MDPI 2023-07-06 /pmc/articles/PMC10377393/ /pubmed/37509547 http://dx.doi.org/10.3390/biomedicines11071908 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report De La Flor, José C. Villa, Daniel Cruzado, Leónidas Apaza, Jacqueline Valga, Francisco Zamora, Rocío Marschall, Alexander Cieza, Michael Deira, Javier Rodeles, Miguel Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors? |
title | Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors? |
title_full | Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors? |
title_fullStr | Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors? |
title_full_unstemmed | Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors? |
title_short | Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors? |
title_sort | efficacy and safety of the use of sglt2 inhibitors in patients on incremental hemodialysis: maximizing residual renal function, is there a role for sglt2 inhibitors? |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377393/ https://www.ncbi.nlm.nih.gov/pubmed/37509547 http://dx.doi.org/10.3390/biomedicines11071908 |
work_keys_str_mv | AT delaflorjosec efficacyandsafetyoftheuseofsglt2inhibitorsinpatientsonincrementalhemodialysismaximizingresidualrenalfunctionistherearoleforsglt2inhibitors AT villadaniel efficacyandsafetyoftheuseofsglt2inhibitorsinpatientsonincrementalhemodialysismaximizingresidualrenalfunctionistherearoleforsglt2inhibitors AT cruzadoleonidas efficacyandsafetyoftheuseofsglt2inhibitorsinpatientsonincrementalhemodialysismaximizingresidualrenalfunctionistherearoleforsglt2inhibitors AT apazajacqueline efficacyandsafetyoftheuseofsglt2inhibitorsinpatientsonincrementalhemodialysismaximizingresidualrenalfunctionistherearoleforsglt2inhibitors AT valgafrancisco efficacyandsafetyoftheuseofsglt2inhibitorsinpatientsonincrementalhemodialysismaximizingresidualrenalfunctionistherearoleforsglt2inhibitors AT zamorarocio efficacyandsafetyoftheuseofsglt2inhibitorsinpatientsonincrementalhemodialysismaximizingresidualrenalfunctionistherearoleforsglt2inhibitors AT marschallalexander efficacyandsafetyoftheuseofsglt2inhibitorsinpatientsonincrementalhemodialysismaximizingresidualrenalfunctionistherearoleforsglt2inhibitors AT ciezamichael efficacyandsafetyoftheuseofsglt2inhibitorsinpatientsonincrementalhemodialysismaximizingresidualrenalfunctionistherearoleforsglt2inhibitors AT deirajavier efficacyandsafetyoftheuseofsglt2inhibitorsinpatientsonincrementalhemodialysismaximizingresidualrenalfunctionistherearoleforsglt2inhibitors AT rodelesmiguel efficacyandsafetyoftheuseofsglt2inhibitorsinpatientsonincrementalhemodialysismaximizingresidualrenalfunctionistherearoleforsglt2inhibitors |